» Articles » PMID: 25929809

HCC-DETECT: a Combination of Nuclear, Cytoplasmic, and Oncofetal Proteins As Biomarkers for Hepatocellular Carcinoma

Abstract

Currently, the search for suitable hepatocellular carcinoma (HCC) biomarkers is very intensive. Besides, efficacy and cost/effectiveness of screening and surveillance of cirrhotics for the diagnosis of HCC is still debated. So, the present study is concerned with the evaluation of cytokeratin-1 (CK-1) and nuclear matrix protein-52 (NMP-52) for identifying HCC. Two-hundred and eighty individuals categorized into three groups [liver fibrosis (F1-F3), cirrhosis (F4), and HCC] constituted this study. Western blot was used for identifying CK-1 and NMP-52 in serum samples. As a result, a single immunoreactive band was shown at 67 and 52 kDa corresponding to CK-1 and NMP-52, respectively. Both CK-1 and NMP-52 bands were cut and electroeluted separately. These markers were quantified in sera using ELISA. Patients with HCC were associated with higher concentrations of CK-1 and NMP-52 than those without HCC with a significant difference (P < 0.0001). CK-1 showed an area under receiver-operating characteristic curve (AUC) of 0.83 with 75 % sensitivity and 82 % specificity while NMP-52 yielded 0.72 AUC with 62 % sensitivity and 70 % specificity for identifying HCC. HCC-DETECT comprising CK-1 and NMP-52 together with AFP was then constructed yielding 0.90 AUC for identifying HCC with 80 % sensitivity and 92 % specificity. HCC-DETECT was then tested for separating HCC from F1-F3 showing 0.94 AUC with 80 % sensitivity and 93 % specificity. In conclusion, CK-1 in conjunction with NMP-52 and AFP could have a potential role for improving the detection of HCC with a high degree of accuracy.

Citing Articles

Anti-hepatocellular carcinoma activities of novel hydrazone derivatives downregulation of interleukin-6.

Nabil A, Abdel-Motaal M, Hassan A, Elshemy M, Asem M, Elwan M RSC Adv. 2024; 14(51):37960-37974.

PMID: 39610815 PMC: 11603412. DOI: 10.1039/d4ra05854b.


Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis.

Omar M, Omran M, Farid K, Tabll A, Shahein Y, Emran T Biomedicines. 2023; 11(7).

PMID: 37509493 PMC: 10377276. DOI: 10.3390/biomedicines11071852.


A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus.

Omran M, Mosaad S, Emran T, Eltaweel F, Farid K J Genet Eng Biotechnol. 2021; 19(1):168.

PMID: 34714420 PMC: 8556404. DOI: 10.1186/s43141-021-00262-8.


Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters.

Montano-Samaniego M, Bravo-Estupinan D, Mendez-Guerrero O, Alarcon-Hernandez E, Ibanez-Hernandez M Front Oncol. 2020; 10:605380.

PMID: 33381459 PMC: 7768042. DOI: 10.3389/fonc.2020.605380.

References
1.
Rampone B, Schiavone B, Confuorto G . Current management of hepatocellular cancer. Curr Oncol Rep. 2010; 12(3):186-92. DOI: 10.1007/s11912-010-0094-3. View

2.
Pienta K, Partin A, Coffey D . Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res. 1989; 49(10):2525-32. View

3.
Moll R . [Cytokeratins as markers of differentiation. Expression profiles in epithelia and epithelial tumors]. Veroff Pathol. 1993; 142:1-197. View

4.
Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T . Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993; 328(25):1797-801. DOI: 10.1056/NEJM199306243282501. View

5.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View